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Abstract 
Repeated pancreatectomy for pancreatic carcinoma is extremely rare. We report two 
such patients who underwent pancreatectomy for carcinoma developing in the 
pancreatic remnant after pylorus-preserving pancreatoduodenectomy (PpPD) for 
invasive pancreatic ductal carcinoma. One patient underwent PpPD for invasive 
pancreatic ductal carcinoma and received adjuvant chemotherapy. Follow-up computed 
tomography (CT) demonstrated a low-density mass in the remnant pancreas, which was 
diagnosed as a carcinoma by endoscopic ultrasound-guided fine-needle aspiration 
cytology 5 years 10 months after PpPD. She underwent curative resection of the remnant 
pancreas and is alive and well 13 months after the second operation. The other patient 
underwent PpPD for invasive pancreatic ductal carcinoma. Follow-up CT showed a 
low-density mass in the remnant pancreas after 2 years 11 months. He received systemic 
chemotherapy with S-1 for 3 months. The tumor shrank, and the patient underwent 
curative resection of the remnant pancreas 3 years 1 month after the initial operation. 
Repeated pancreatectomy may provide a chance of long survival for patients with 
carcinoma developing in the remnant pancreas after pancreatectomy if the recurrence 
occurring at long term is limited to the remnant pancreas.  
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the carcinomas with poor 
prognosis [1]. Complete surgical resection is the only curative treatment for PDAC. 
However, survival rates after curative resection are still less than 20% [2, 3]. Local 
recurrence in the remnant pancreas, multiple liver metastases, and peritoneal 
dissemination frequently occur even after curative resection. The chance of repeated 
pancreatectomy for PDAC developing in the remnant pancreas is quite low [4–13]. 
However, recent advancement of chemotherapy improves survival rates and may lead to 
an increase in the chance of repeated pancreatectomy. We report two patients with 
repeated pancreatectomy for PDAC developing in the remnant pancreas after 
pylorus-preserving pancreatoduodenectomy (PpPD) for invasive PDAC.  
Patient 1 
A 63-year-old woman with previous right modified mastectomy for breast cancer (pStage II, 
pT2, pN0, M0, according to the International Union Against Cancer (UICC) TNM classification of 
malignant cancer) in April 1995 presented with loss of appetite, itching, and jaundice in July 2002. 
Her serum level of carbohydrate antigen 19-9 (CA19-9) was elevated to 57.9 U/ml. Ultrasonography 
and computed tomography (CT) showed dilation of the main pancreatic duct and common bile 
duct without a pancreatic head mass. Endoscopic retrograde cholangiopancreatography (ERCP) 
demonstrated a stricture of both the main pancreatic duct and common bile duct in the head of the 
pancreas. Endoscopic ultrasound showed a hypoechoic mass, 25 × 16 mm in size, in the head of the 
pancreas. These findings were consistent with a diagnosis of pancreatic head carcinoma. She underwent 
PpPD and extended lymph node dissection in August 2002. Histopathologically, the tumor consisted of 
well to moderately differentiated tubular adenocarcinoma invading the adipose tissue, bile duct and 
duodenal wall (fig. 1). The surgical margin of the resected specimen was free of cancer cells. Regional 
lymph nodes were metastasized (pStage III, pT3, pN1, M0, according to the UICC TNM classification). 
After operation, adjuvant therapy with 5-FU and folinic acid was carried out over 6 months. 
In August 2004, her blood sugar level was elevated and a treatment of diabetes mellitus was 
started with oral antidiabetic agents in August 2004. The serum level of CA19-9 rose to 49 U/ml in 
February 2008. CT demonstrated a low-density mass, 25 × 21 mm in size, in the remnant pancreas in 
July 2008 (fig. 2). The mass was diagnosed as PDAC by endoscopic ultrasound-guided fine-needle 
aspiration cytology. The carcinoma was limited inside the pancreatic tissue without distant metastasis 
and peritoneal dissemination as examined by ultrasonography, CT, magnetic resonance 
cholangiopancreatography (MRCP) (fig. 3), and positron emission tomography. We performed 
resection of the remnant pancreas with splenectomy and lymph node dissection in October 2008, 
5 years 11 months after PpPD for the initial PDAC. Histopathologically, the second tumor consisted of a 
well differentiated tubular adenocarcinoma and was limited inside the pancreatic tissue with free 
surgical margins and regional lymph node metastases (fig. 4). Her postoperative course was uneventful 
and the CA19-9 level decreased to normal. One month after the second operation, systemic 
chemotherapy with S-1, 5-chloro-2,4-dihydropyrimidine and potassium oxonate was initiated. The 
patient is alive and well 13 months after the second operation. 
Patient 2 
A 56-year-old man presented with jaundice in February 2007. His serum level of CA19-9 and 
carcinoembryonic antigen was elevated to 62.2 U/ml and 9.6 ng/ml, respectively. CT showed dilation 
of the pancreatic duct and bile duct with an irregular low-density mass, 15 × 12 mm in size, in the 
pancreatic head. ERCP demonstrated an obstruction of both the main pancreatic duct and bile duct. 
These findings were consistent with a diagnosis of pancreatic head carcinoma. He underwent PpPD 
with extended lymph node dissection in February 2006. Histological examination showed poorly 
differentiated adenocarcinoma invading the surrounding adipose tissue and bile duct. The surgical  
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margin was free of atypical cells. Regional lymph nodes were metastasized (pStage IIb, pT1, pN1, M0, 
according to the UICC TNM classification). After operation, adjuvant chemotherapy with gemcitabine 
was carried out for 12 months. 
The serum CA19-9 level rose to 86 U/ml in November 2008. Follow-up CT demonstrated a 
low-density mass, 15 × 14 mm in size, in the remnant pancreas (fig. 5). He received chemotherapy with 
S-1 for 3 months and CT scan showed the tumor size decreasing to 10 mm without distant metastasis. 
We performed resection of the remnant pancreas with splenectomy and lymph node dissection in 
March 2009. Histopathologically, the second tumor was a poorly differentiated adenocarcinoma limited 
inside the pancreatic tissue with free surgical margin and regional lymph node metastases. The 
postoperative course was uneventful and the patient has been alive and well for 7 months at the time of 
writing. 
Discussion 
Pancreatic carcinoma is known to have a poor prognosis and frequently develops 
recurrence even after curative resection [14]. The major recurrence pattern of PDAC 
is local spread in the remnant pancreas, multiple liver metastases and peritoneal 
dissemination within 1–2 years after resection [15, 16]. In the present patients, surgical 
resection of the remnant pancreas was performed because the recurrence of PDAC after 
PpPD was limited to the remnant pancreas without distant metastasis, nodal involvement 
and peritoneal dissemination. There have been anecdotal reports of repeated 
pancreatectomy for recurrent PDAC in the remnant pancreas [4–13]. Some of the 
previous reports demonstrated long survival after surgical resection for the second PDAC 
[5, 6, 8, 10, 12]. These patients and our patients show the same clinical feature, that is, 
curative resection with negative surgical margins at both the first and second operations. 
The effectiveness of repeated pancreatectomy for PDAC in the remnant pancreas is 
obscure because of the lack of a sufficient number of patients, but the safety of repeated 
pancreatectomy has been reported recently [9]. We believe that repeated pancreatectomy 
may provide good results in selected patients in whom complete removal of PDAC in the 
remnant pancreas can be achieved. 
It is difficult to clarify whether PDAC developing in the remnant pancreas is a local 
recurrence or a second primary carcinoma. According to Schnelldorfer et al. [3], 5-year 
survival after PpPD or pancreatoduodenectomy for PDAC was no guarantee of cure, 
because 16% of this subset died of PDAC up to 7.8 years after the operation. On the 
other hand, Launois et al. [17] observed the incidence of 32% of multifocal carcinomas in 
the pancreas in a series of 47 total pancreatectomies for patients with PDAC. Progression 
of atypical ductal hyperplasia or carcinoma in situ to an invasive PDAC has been 
documented [18]. A minute cancerous lesion may coexist in the remnant pancreas at the 
initial operation. In our patients, the second carcinoma seems to be a recurrent lesion 
because both the first and second cancers showed similar histological characteristics, even 
with the long interval period between the first and second operations. Although it is 
obscure whether PDAC in the remnant pancreas is a local recurrence or not, periodic 
examinations including measurement of tumor markers and imaging studies such as CT 
scan might have an important role for early detection of PDAC developing in the 
remnant pancreas after pancreatectomy for PDAC. 
Recent advancement of adjuvant and neoadjuvant therapy including chemotherapy 
and radiotherapy improves the survival benefit in patients undergoing curative resection 
of PDAC [19–21]. Adjuvant therapy may inhibit the growth of carcinoma in the remnant  
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pancreas after pancreatectomy for PDAC. Some PDAC is chemosensitive and 
preoperative chemotherapy provides a histopathological response and a high R0 resection 
rate [22]. In our second patient administration of S-1 made the recurrent tumor shrink, 
and curative resection was performed. Effects of chemotherapy may increase the chance 
of curative resection of a secondary primary or recurrent pancreatic carcinoma in the 
remnant pancreas.  
In conclusion, curative resection for PDAC developing in the remnant pancreas after 
PpPD for PDAC may be possible as in our patients. Repeated pancreatectomy may 
provide a chance of long-term survival if the recurrence of PDAC is limited to the 
remnant pancreas. 
 
 
 
 
 
 
Fig. 1. High-power view of the histopathologic specimen of the first operation demonstrating a well to 
moderately differentiated tubular adenocarcinoma (HE, 400×).  
 
 
 
Fig. 2. CT scan showing a pancreatic mass limited inside the pancreas without distant metastasis and 
peritoneal dissemination. 
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Fig. 3. MRCP shows an obstruction of both the main pancreatic duct and bile duct. 
 
 
 
Fig. 4. High-power view of the histopathologic specimen of the second operation (HE, 400×). 
Histopathologically, the second tumor was a well differentiated tubular adenocarcinoma. 
 
 
 
Fig. 5. Follow-up CT scan demonstrating a low-density mass, 15 × 14 mm in size, in the remnant 
pancreas. 
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